Page last updated: 2024-11-07

clevidipine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

clevidipine: a calcium channel blocker and antihypertensive agent; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID153994
CHEMBL ID1237132
CHEBI ID135738
SCHEMBL ID115522
MeSH IDM0303812

Synonyms (91)

Synonym
clevelox
h-324/38
clevidipine
clevidipine butyrate
cleviprex
CHEBI:135738
5-o-(butanoyloxymethyl) 3-o-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
D08892
clevidipine (usan/inn)
cleviprex (tn)
167221-71-8
166432-28-6
FT-0659562
methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dime thyl-3,5-pyridinedicarboxylate
A810832
butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, methyl (1-oxobutoxy)methyl ester
methyl (1-oxobutoxy)methyl 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylate
clevidipine [usan:inn]
h324/38
19o2gp3b7q ,
h 324/38
rac-clevidipine
unii-19o2gp3b7q
(butanoyloxy)methyl methyl (4rs)-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
CHEMBL1237132
clevidepine butyrate
clevidepine
FT-0688416
S2080
AKOS015896325
4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 3-methyl 5-[(1-oxobutoxy)methyl] ester
clevidipine [orange book]
clevidipine [mi]
clevidepine [vandf]
clevidepine butyrate [vandf]
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-((1-oxobutoxy)methyl) ester
DB04920
clevidipine butyrate [vandf]
clevidipine [vandf]
clevidipine [usan]
clevidipine butyrate [orange book]
clevidipine [mart.]
clevidipine [inn]
clevidipine [who-dd]
CS-1427
HY-17436
SCHEMBL115522
tox21_113923
cas-167221-71-8
dtxcid7031450
NCGC00262928-01
dtxsid6057661 ,
gtpl7468
o3-(butanoyloxymethyl) o5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
3-((butyryloxy)methyl) 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
AC-24370
bdbm50088387
HMS3604H21
AB01566888_01
J-520103
SR-01000945183-1
sr-01000945183
SR-01000945183-2
3,5-pyridinedicarboxylic acid, 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-, 3-methyl 5-[(1-oxobutoxy)methyl] ester
HMS3651G10
cleviprex (clevidipine)
SW220087-1
KPBZROQVTHLCDU-UHFFFAOYSA-N
BCP22687
Q5132338
butyroxymethyl methyl 4-(2',3'-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylat
mfcd00940070
AS-19935
3-[(butyryloxy)methyl] 5-methyl 4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate
4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylic aicd 3-[(butyryloxy)methyl] 5-methyl ester
C3503
EX-A2898
AMY22141
EN300-119519
HMS3884L03
CCG-269294
clevidipine butyrate;clevidipine
BCP22676
methyl 5-{[(butanoyloxy)methoxy]carbonyl}-4-(2,3-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3-carboxylate
clevidipine (mart.)
clevipidine
clevidipinum
clevidipino
c08ca16
Z1521553844

Research Excerpts

Overview

Clevidipine is a new intravenous calcium antagonist with rapid onset of action and short half-life that has no residual effect and does not produce arterial hypotension after tumour resection. Clevidipsine is an ester-containing antihypertensive agent that undergoes rapid hydrolysis in blood.

ExcerptReferenceRelevance
"Clevidipine is an ultra-rapid-acting intravenous antihypertensive agent used for hemodynamic control in adult surgical patients."( Effect of clevidipine on intracranial pressure in pediatric neurosurgical patients: a single-center retrospective review.
Casazza, M; Chang, N; Moss, J; Rasmussen, L; Vadasz, E, 2023
)
2.03
"Clevidipine is a new intravenous calcium antagonist with rapid onset of action and short half-life that has no residual effect and does not produce arterial hypotension after tumour resection."( Clevidipine for hypertension treatment in pheochromocytoma surgery.
Arbonés-Aran, E; Lorente-Poch, L; Luis-García, C; Teixell-Aleu, C; Trillo-Urrutia, L, 2018
)
2.64
"Clevidipine is a novel, ultra-short acting dihydropyridine. "( Clevidipine for acute hypertension in patients with subarachnoid hemorrhage: a pilot study.
Abdelhak, T; Corry, JJ; James, E; Mays-Wilson, K; Mitsias, P; Rehman, MF; Schultz, L; Varelas, PN, 2014
)
3.29
"Clevidipine is a rapidly acting, arterial selective intravenous calcium-channel blocker."( Clevidipine in acute heart failure: Results of the A Study of Blood Pressure Control in Acute Heart Failure-A Pilot Study (PRONTO).
Chandra, A; Char, D; Collins, S; Der Sahakian, G; Ding, L; Dunbar, L; Fermann, G; Fonarow, GC; Garrison, N; Hu, MY; Jourdain, P; Laribi, S; Levy, P; Mebazaa, A; Möckel, M; Mueller, C; Peacock, WF; Ray, P; Singer, A; Ventura, H; Weiss, M, 2014
)
2.57
"Clevidipine is an ester-containing antihypertensive agent that undergoes rapid hydrolysis in blood. "( Screening of stabilizers for LC-MS/MS analysis of clevidipine and its primary metabolite in dog whole blood.
Cao, P; Hu, Y; Huang, J; Huang, L; Li, G; Qin, L; Qiu, L; Si, L; Zhao, S; Zhu, W, 2015
)
2.11
"Clevidipine is a short acting, esterase metabolized, calcium channel antagonist administered as a continuous infusion for control of hypertension. "( The Effect of Clevidipine on Cerebral Blood Flow Velocity and Carbon Dioxide Reactivity in Human Volunteers.
Drummond, JC; Gierl, BT; Lemkuil, BP; Minokadeh, A; Nguyen, LC; Patel, PM; Pearn, ML, 2016
)
2.24
"Clevidipine is an ultrashort-acting drug for rapid reduction of blood pressure by selectively acting on the L-type Ca2+ channels on arteriolar smooth muscle. "( Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis.
Abad-Gurumeta, A; Bergese, SD; Calvo-Vecino, JM; Casans-Francés, R; Espinosa, A; López-Timoneda, F; Ripollés-Melchor, J; Zuleta-Alarcon, A, 2016
)
2.2
"Clevidipine is an ultrafast-acting drug that is highly effective for management of perioperative arterial hypertension. "( Perioperative Use of Clevidipine: A Systematic Review and Meta-Analysis.
Abad-Gurumeta, A; Bergese, SD; Calvo-Vecino, JM; Casans-Francés, R; Espinosa, A; López-Timoneda, F; Ripollés-Melchor, J; Zuleta-Alarcon, A, 2016
)
2.2
"Clevidipine is an investigational agent undergoing late-stage clinical development to evaluate its potential as a novel short-acting intravenous agent for treating acute hypertension, either in hypertensive emergencies encountered in the emergency department and intensive care units, or in the perioperative period."( Drug evaluation of clevidipine for acute hypertension.
Noviawaty, I; Qureshi, AI; Uzun, G, 2008
)
2.12
"Clevidipine is an effective agent for reducing acute elevation in blood pressure in various settings, including hypertensive emergencies and perioperative hypertension with a good safety profile."( Drug evaluation of clevidipine for acute hypertension.
Noviawaty, I; Qureshi, AI; Uzun, G, 2008
)
2.12
"Clevidipine is a novel, rapidly acting dihydropyridine L-type calcium channel blocker with an ultrashort half-life that decreases arterial blood pressure (BP)."( The ECLIPSE trials: comparative studies of clevidipine to nitroglycerin, sodium nitroprusside, and nicardipine for acute hypertension treatment in cardiac surgery patients.
Aronson, S; Cheung, AT; Dyke, CM; Kereiakes, DJ; Levy, JH; Lumb, PD; Newman, MF; Stierer, KA, 2008
)
1.33
"Clevidipine is an arterial, selective, dihydropyridine calcium channel blocker with an ultrashort half-life. "( Clevidipine in the treatment of perioperative hypertension: assessing safety events in the ECLIPSE trials.
Aronson, S, 2009
)
3.24
"Clevidipine is a new third-generation dihydropyridine calcium-channel blocker available for intravenous management of moderate-to-severe hypertension. "( Clevidipine: an ultra short-acting calcium channel antagonist for acute hypertension.
Kenyon, KW, 2009
)
3.24
"Clevidipine butyrate is an ultrashort-acting intravenous dihydropyridine calcium-channel blocker that has been approved by the FDA for the reduction of blood pressure when oral therapy is not feasible. "( Clevidipine butyrate: a promising new drug for the management of acute hypertension.
Bergese, SD; Puente, EG, 2010
)
3.25
"Clevidipine is an intravenous, ultra-short-acting, third-generation dihydropyridine calcium channel antagonist with selectivity for arteriolar vasodilatation."( Clevidipine for the treatment of severe hypertension in adults.
Ma, K; Nguyen, HM; Pham, DQ, 2010
)
2.52
"Clevidipine is a new lipophilic, short-acting, third-generation dihydropyridine calcium channel blocker (CCB) approved for use in the management of acute hypertension when oral agents are not feasible. "( Clevidipine: a new intravenous option for the management of acute hypertension.
Ebiasah, R; Erowele, GI; Green, W; Ndefo, UA, 2010
)
3.25
"Clevidipine is a third-generation parenteral dihydropyridine calcium channel blocker that received United States Food and Drug Administration approval in August 2008 for blood pressure reduction when oral therapy is not feasible or desirable."( Clevidipine: a short-acting intravenous dihydropyridine calcium channel blocker for the management of hypertension.
DeGrado, JR; Erickson, AL; Fanikos, JR, 2010
)
2.52
"Clevidipine is a rapidly acting calcium channel antagonist."( Intraoperative administration of clevidipine to prevent vasospasm after radial and internal mammary artery grafts during coronary artery bypass grafting.
Meyer, T; Patel, M; Tharakan, A; Tobias, JD, 2012
)
1.38
"Clevidipine is a third-generation calcium channel antagonist of the dihydropyridine group. "( Preliminary experience with clevidipine in the pediatric population.
Tobias, JD; Towe, E,
)
1.87
"Clevidipine is a rapidly acting (t½∼1 min) intravenous (IV) dihydropyridine calcium-channel blocker metabolized by blood and tissue esterases and may be useful in patients with RD."( Clevidipine for severe hypertension in patients with renal dysfunction: a VELOCITY trial analysis.
Dunbar, L; Ebrahimi, R; Frank Peacock, W; Pollack, CV; Varon, J, 2011
)
2.53
"Clevidipine is an ultrashort-acting, intravenous calcium channel antagonist. "( Clevidipine for controlled hypotension during spinal surgery in adolescents.
Hoernschemeyer, DG; Tobias, JD, 2011
)
3.25
"Clevidipine is an ultra-shorting acting, intravenous calcium channel antagonist of the dihydropyridine class. "( Clevidipine for controlled hypotension during spinal surgery in adolescents.
Tobias, JD, 2011
)
3.25
"Clevidipine is a rapidly-acting intravenous dihydropyridine antihypertensive acting via calcium channel blockade. "( Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.
Hu, MY; Komjathy, SF; Marbury, TC; Mould, DR; Smith, WB; Sumeray, MS; Williams, GC, 2012
)
2.07
"Clevidipine is a new ultrashort-acting dihydropyridine calcium antagonist developed for blood pressure regulation during cardiac surgery. "( Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
Ericsson, H; Johansson, L; Rydén, L; Segawa, D; Sjöquist, PO; Wang, QD, 2002
)
1.98
"Clevidipine is an ultrashort-acting vasoselective calcium antagonist under development for short-term intravenous control of blood pressure. "( Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
Ericsson, H; Nordlander, M; Rydén, L; Sjöquist, PO, 2004
)
2.01
"Clevidipine is a short-acting dihydropyridine calcium channel antagonist under development for treatment of perioperative hypertension. "( Human cytochrome p450 induction and inhibition potential of clevidipine and its primary metabolite h152/81.
Blanchard, AP; Chandler, C; Clark, RJ; Crespi, CL; Dehal, SS; Ho, T; Johnson, J; Stresser, DM; Wong, J; Zhang, JG, 2006
)
2.02
"Clevidipine is an ultra-short-acting, vascular-selective, dihydropyridine calcium antagonist that is being developed for intravenous use in acute hospitalized patients."( New drugs for hypertension: what do they offer?
Gradman, AH; Vivas, Y, 2006
)
1.06
"Clevidipine is a new, vascular-selective, dihyrdopyridine Ca(2+) channel blocker, which exerts its hemodynamic effects through selective arterial vasodilation without effects on the venous circulation."( New therapeutic perspectives with clevidipine: an ultra-short-acting intravenous Ca2+ channel blocker.
Gradman, AH; Vivas, Y, 2007
)
1.34
"Clevidipine is an ultrashort-acting, third-generation IV dihydropyridine calcium channel blocker that exerts rapid and titratable arterial blood pressure reduction, with fast termination of effect due to metabolism by blood and tissue esterases. "( Clevidipine effectively and rapidly controls blood pressure preoperatively in cardiac surgery patients: the results of the randomized, placebo-controlled efficacy study of clevidipine assessing its preoperative antihypertensive effect in cardiac surgery-1
Aronson, S; Gitter, R; Grigore, AM; Kereiakes, DJ; Levy, JH; Mancao, MY; Newman, MF, 2007
)
3.23
"Clevidipine is a high clearance drug, which is rapidly metabolized to the corresponding inactive acid. "( Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.
Ericsson, H; Fakt, C; Höglund, L; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG; Sunzel, M, 1999
)
2.01
"Clevidipine is a new vascular selective calcium channel antagonist of the dihydropyridine type, structurally related to felodipine. "( Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.
Björkman, JA; Ericsson, H; Nordlander, M; Regårdh, CG; Tholander, B, 1999
)
2
"Clevidipine is a high clearance drug with extremely short half-lives."( Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
Ericsson, H; Fakt, C; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG; Sohtell, L; Sunzel, M, 1999
)
1.25
"Clevidipine is an ultra-short-acting calcium antagonist developed for reduction and control of blood pressure during cardiac surgery. "( Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
Bredberg, U; Ericsson, H; Eriksson, U; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG, 2000
)
2
"Clevidipine is a high clearance drug with a small volume of distribution, resulting in extremely short half-lives in healthy subjects. "( Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
Bredberg, U; Ericsson, H; Eriksson, U; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG, 2000
)
2
"Clevidipine is a new lipophilic, ultra-short acting 1, 4-dihydropyridine calcium channel antagonist for intraoperative use. "( Effect of clevidipine, an ultra-short acting 1,4-dihydropyridine calcium channel blocking drug, on the potency of isoflurane in rats and dogs.
de Wolff, MH; Leather, HA; Wouters, PF, 2000
)
2.15
"Clevidipine is a new vascular-selective, calcium channel antagonist of the dihydropyridine type with an ester side chain susceptible to esterase metabolism. "( Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass.
Dunning, J; Ericsson, H; Jolin-Mellgård, A; Latimer, R; Milner, Q; Mur, D; Nordlander, M; Vuylsteke, A, 2000
)
2.01
"Clevidipine is a calcium channel antagonist with a very short duration of action that effectively decreases systemic vascular resistance and mean arterial pressure without changing heart rate, cardiac index, or cardiac filling pressures."( Clevidipine in adult cardiac surgical patients: a dose-finding study.
Bailey, JM; Brister, NW; Jolin-Mellgard, A; Levy, JH; Lu, W; Nordlander, M; Prielipp, RC; Ramsay, JG; Roach, GW; Shore-Lesserson, L, 2002
)
3.2

Effects

Clevidipine has a high clearance (0.05 L/min/kg) and is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood.

Clevidipine has potent spasmolytic effects in peripheral arteries at doses that are sub-clinical for BP lowering. In hypertensive acute heart failure, clevidipine, but not other DHPs, provides dyspnea relief, partially independent of BP reduction. Clevidipsine has been evaluated in four Phase I studies, nine Phase II studies and six Phase III clinical studies.

ExcerptReferenceRelevance
"Clevidipine has a half-life of approximately two minutes after i.v."( Clevidipine: a new intravenous option for the management of acute hypertension.
Ebiasah, R; Erowele, GI; Green, W; Ndefo, UA, 2010
)
2.52
"Clevidipine has an extremely short half-life of approximately 1 minute as it is rapidly metabolized by blood and tissue esterases."( Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review.
Awad, AS; Goldberg, ME, 2010
)
1.52
"Clevidipine has an ultrashort blood half-life, and ischemic durati"( Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
Ericsson, H; Johansson, L; Rydén, L; Segawa, D; Sjöquist, PO; Wang, QD, 2002
)
1.26
"Clevidipine has a high clearance (0.05 L/min/kg) and is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood."( Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
Ericsson, H; Nordlander, M; Rydén, L; Sjöquist, PO, 2004
)
1.29
"Clevidipine has potent spasmolytic effects in peripheral arteries at doses that are sub-clinical for BP lowering and, in hypertensive acute heart failure, clevidipine, but not other DHPs, provides dyspnea relief, partially independent of BP reduction."( High affinity complexes of pannexin channels and L-type calcium channel splice-variants in human lung: Possible role in clevidipine-induced dyspnea relief in acute heart failure.
Campagna, JA; Conner, GE; Dahl, GP; Larsson, HP; Qiu, F; Spindler, E; Wang, J, 2016
)
1.36
"Clevidipine has been evaluated in four Phase I studies, nine Phase II studies and six Phase III clinical studies. "( Drug evaluation of clevidipine for acute hypertension.
Noviawaty, I; Qureshi, AI; Uzun, G, 2008
)
2.12
"Clevidipine has unique pharmacodynamic and pharmacokinetic properties that enable the fast, safe and adequate reduction of blood pressure in hypertensive emergencies, with unique precision necessary to maintain the target blood pressure range."( Clevidipine butyrate: a promising new drug for the management of acute hypertension.
Bergese, SD; Puente, EG, 2010
)
2.52
"Clevidipine has a half-life of approximately two minutes after i.v."( Clevidipine: a new intravenous option for the management of acute hypertension.
Ebiasah, R; Erowele, GI; Green, W; Ndefo, UA, 2010
)
2.52
"Clevidipine has an extremely short half-life of approximately 1 minute as it is rapidly metabolized by blood and tissue esterases."( Role of clevidipine butyrate in the treatment of acute hypertension in the critical care setting: a review.
Awad, AS; Goldberg, ME, 2010
)
1.52
"Clevidipine has an ultrashort blood half-life, and ischemic durati"( Time-dependent cardioprotection with calcium antagonism and experimental studies with clevidipine in ischemic-reperfused pig hearts: part I.
Ericsson, H; Johansson, L; Rydén, L; Segawa, D; Sjöquist, PO; Wang, QD, 2002
)
1.26
"Clevidipine has a high clearance (0.05 L/min/kg) and is rapidly hydrolyzed to inactive metabolites by esterases in arterial blood."( Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
Ericsson, H; Nordlander, M; Rydén, L; Sjöquist, PO, 2004
)
1.29

Treatment

ExcerptReferenceRelevance
"Clevidipine-treated patients had a significantly lower incidence of treatment failure than placebo patients [8.2% (5 of 61) vs 79.6% (39 of 49), P < 0.0001]. "( Treatment of acute postoperative hypertension in cardiac surgery patients: an efficacy study of clevidipine assessing its postoperative antihypertensive effect in cardiac surgery-2 (ESCAPE-2), a randomized, double-blind, placebo-controlled trial.
Aronson, S; Corwin, HL; Gandhi, SD; Lumb, PD; Newman, MF; Singla, N; Sladen, RN; Warltier, DC, 2008
)
2.01

Toxicity

Clevidipine monotherapy was effective and safe for rapid BP reduction in this cohort of critically ill ICH patients.

ExcerptReferenceRelevance
"Clevidipine, dosed in a non-weight-based manner, was safe and effective in a cohort of patients with severe hypertension at a starting dose of 2 mg per hour, followed by simple titration during 18 hours or more of continuous infusion."( Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension.
Dunbar, L; Ebrahimi, R; Garrison, NA; Peacock, WF; Pollack, CV; Varon, J, 2009
)
3.24
"Clevidipine monotherapy was effective and safe for rapid BP reduction in this cohort of critically ill ICH patients."( Clevidipine rapidly and safely reduces blood pressure in acute intracerebral hemorrhage: the ACCELERATE trial.
Bergese, S; Graffagnino, C; Hu, MY; LaPointe, M; Lazaridis, C; Lee, K; Love, J; Lynch, G; Schneider, D; Williams, GC, 2013
)
3.28

Pharmacokinetics

The duration of the infusion had negligible effect on the pharmacokinetic parameters, and the context-sensitive half-time for clevidipine was less than 1 min. This study supports the use of up to 72 h of IV cleidipine therapy for the management of blood pressure.

ExcerptReferenceRelevance
" The tmax value of the primary metabolite, and a virtually identical value of the initial half-life and the half-life for elimination from the central compartment, indicate that the initial rapid decline of the post-infusion blood levels is mainly due to elimination rather than distribution."( Pharmacokinetics and pharmacodynamics of clevidipine in healthy volunteers after intravenous infusion.
Ericsson, H; Fakt, C; Höglund, L; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG; Sunzel, M, 1999
)
0.57
" According to the results, clevidipine is a high-clearance drug with a relatively small volume of distribution, resulting in an extremely short half-life in all species studied."( Pharmacokinetics of new calcium channel antagonist clevidipine in the rat, rabbit, and dog and pharmacokinetic/pharmacodynamic relationship in anesthetized dogs.
Björkman, JA; Ericsson, H; Nordlander, M; Regårdh, CG; Tholander, B, 1999
)
0.85
"To investigate the tolerability and safety of clevidipine in healthy male volunteers during intravenous infusion at gradually increasing dose rates and to obtain preliminary information on the pharmacokinetics and pharmacodynamic effects of the drug."( Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
Ericsson, H; Fakt, C; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG; Sohtell, L; Sunzel, M, 1999
)
0.79
" Applying the population approach to the sparse data on clevidipine concentrations, an open two compartment pharmacokinetic model was found to be the best model in describing the disposition of the drug."( Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
Ericsson, H; Fakt, C; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG; Sohtell, L; Sunzel, M, 1999
)
0.77
" A simple Emax model adequately describes the relationship between the pharmacodynamic response (MAP/HR) and the blood concentrations of clevidipine."( Clinical and pharmacokinetic results with a new ultrashort-acting calcium antagonist, clevidipine, following gradually increasing intravenous doses to healthy volunteers.
Ericsson, H; Fakt, C; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG; Sohtell, L; Sunzel, M, 1999
)
0.73
" Arterial and venous blood samples were drawn for pharmacokinetic evaluation, and blood pressure and heart rate were recorded."( Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
Bredberg, U; Ericsson, H; Eriksson, U; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG, 2000
)
0.56
" The duration of the infusion had negligible effect on the pharmacokinetic parameters, and the context-sensitive half-time for clevidipine, simulated from the mean pharmacokinetic parameters derived after 24 h infusion at the highest dose, was less than 1 min."( Pharmacokinetics and arteriovenous differences in clevidipine concentration following a short- and a long-term intravenous infusion in healthy volunteers.
Bredberg, U; Ericsson, H; Eriksson, U; Jolin-Mellgård, A; Nordlander, M; Regårdh, CG, 2000
)
0.77
" Mixed venous and arterial blood samples were taken for pharmacokinetic analysis and calculation of pulmonary extraction ratio."( Pharmacokinetics and pulmonary extraction of clevidipine, a new vasodilating ultrashort-acting dihydropyridine, during cardiopulmonary bypass.
Dunning, J; Ericsson, H; Jolin-Mellgård, A; Latimer, R; Milner, Q; Mur, D; Nordlander, M; Vuylsteke, A, 2000
)
0.57
" The derived pharmacokinetic parameters were used to simulate the time for 50 and 90% postinfusion decline following various infusion times of rac-clevidipine."( Enantioselective pharmacokinetics of the enantiomers of clevidipine following intravenous infusion of the racemate in essential hypertensive patients.
Ericsson, H; Lindmark, BO; Löfdahl, P; Regårdh, CG; Schwieler, J; Thulin, T, 2001
)
0.76
" Its half-life in patients undergoing cardiac surgery is less than one min."( Pharmacodynamic, pharmacokinetic and clinical effects of clevidipine, an ultrashort-acting calcium antagonist for rapid blood pressure control.
Ericsson, H; Nordlander, M; Rydén, L; Sjöquist, PO, 2004
)
0.57
" pharmacokinetic data on 670 drugs representing, to our knowledge, the largest publicly available set of human clinical pharmacokinetic data."( Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Lombardo, F; Obach, RS; Waters, NJ, 2008
)
0.35
"This study supports the use of up to 72 h of IV clevidipine therapy for the management of blood pressure, with consistent pharmacokinetic/pharmacodynamic characteristics and context insensitive half-life across the dose ranges evaluated."( Pharmacokinetics, pharmacodynamics, and safety of clevidipine after prolonged continuous infusion in subjects with mild to moderate essential hypertension.
Hu, MY; Komjathy, SF; Marbury, TC; Mould, DR; Smith, WB; Sumeray, MS; Williams, GC, 2012
)
0.89
" The analytical method was applied to support a pharmacokinetic study of simultaneous determination of clevidipine and H152/81 in ten healthy beagle dogs."( Simultaneous determination of clevidipine and its primary metabolite in dog plasma by liquid chromatography-tandem mass spectrometry: Application to pharmacokinetic study.
Chen, H; He, X; Jia, M; Li, H; Li, W; Ni, Y; Xu, M; Zhou, Y, 2014
)
0.91
" To characterize its pharmacokinetic profiles in dogs, a simple, rapid and sensitive liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed and validated for quantitation of clevidipine in dog blood."( Quantitation of clevidipine in dog blood by liquid chromatography tandem mass spectrometry: application to a pharmacokinetic study.
Chen, Y; Gu, Y; Liu, C; Liu, Y; Si, D; Wei, H, 2014
)
0.94
"The purpose of the current study was to examine the pharmacokinetic profiles and tissue distribution of clevidipine, an ultra-short-acting calcium antagonist in Beagle dogs and Sprague-Dawley rats, respectively."( Pharmacokinetics and tissue distribution of clevidipine and its metabolite in dogs and rats.
Chen, H; He, XM; Li, HQ; Li, WY; Ni, Y; Xu, MZ; Zhou, Y, 2014
)
0.88
"This present study was designed to investigate the pharmacokinetic profiles and tissue distribution characteristics of clevidipine and its primary metabolite H152/81 in rats following a single intravenous administration of clevidipine butyrate injectable emulsion."( Pharmacokinetics and tissue distribution study of clevidipine and its primary metabolite H152/81 in rats.
Ding, L; Li, Q; Li, T; Sun, L; Wang, Y; Yang, W; Zhao, L, 2018
)
0.94

Bioavailability

ExcerptReferenceRelevance
" The cardioprotective effect of clevidipine is suggested to be dependent on maintained local bioavailability of NO."( Short-acting calcium antagonist clevidipine protects against reperfusion injury via local nitric oxide-related mechanisms in the jeopardised myocardium.
Gonon, A; Gourine, A; Pernow, J; Sjöquist, PO, 2001
)
0.88

Dosage Studied

Clevidipine was safe and effective in a cohort of patients with severe hypertension at a starting dose of 2 mg per hour. In phase 2, the normotensive phase, a clevidipine dose-response relationship was established.

ExcerptRelevanceReference
" In phase 2 (n=9), the normotensive phase, a clevidipine dose-response relationship was established."( Coronary and systemic hemodynamic effects of clevidipine, an ultra-short-acting calcium antagonist, for treatment of hypertension after coronary artery surgery.
Jolin-Mellgård, A; Kieler-Jensen, N; Nordlander, M; Ricksten, SE, 2000
)
0.83
"Clevidipine, dosed in a non-weight-based manner, was safe and effective in a cohort of patients with severe hypertension at a starting dose of 2 mg per hour, followed by simple titration during 18 hours or more of continuous infusion."( Clevidipine, an intravenous dihydropyridine calcium channel blocker, is safe and effective for the treatment of patients with acute severe hypertension.
Dunbar, L; Ebrahimi, R; Garrison, NA; Peacock, WF; Pollack, CV; Varon, J, 2009
)
3.24
"The pharmacology, pharmacokinetics, efficacy, safety, dosage and administration, and place in therapy of clevidipine are reviewed."( Clevidipine: a new intravenous option for the management of acute hypertension.
Ebiasah, R; Erowele, GI; Green, W; Ndefo, UA, 2010
)
2.02
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
dihydropyridine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (13)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.02120.006038.004119,952.5996AID1159521; AID1159523
AR proteinHomo sapiens (human)Potency9.28280.000221.22318,912.5098AID1259243; AID1259247
nuclear receptor subfamily 1, group I, member 3Homo sapiens (human)Potency3.75780.001022.650876.6163AID1224838
progesterone receptorHomo sapiens (human)Potency33.49150.000417.946075.1148AID1346795
cytochrome P450 family 3 subfamily A polypeptide 4Homo sapiens (human)Potency2.75400.01237.983543.2770AID1645841
pregnane X nuclear receptorHomo sapiens (human)Potency2.98490.005428.02631,258.9301AID1346982
GVesicular stomatitis virusPotency1.50920.01238.964839.8107AID1645842
cytochrome P450 2D6Homo sapiens (human)Potency13.80290.00108.379861.1304AID1645840
Interferon betaHomo sapiens (human)Potency11.25810.00339.158239.8107AID1347407; AID1645842
HLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)Potency1.50920.01238.964839.8107AID1645842
Inositol hexakisphosphate kinase 1Homo sapiens (human)Potency1.50920.01238.964839.8107AID1645842
cytochrome P450 2C9, partialHomo sapiens (human)Potency1.50920.01238.964839.8107AID1645842
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Bile salt export pumpHomo sapiens (human)IC50 (µMol)36.35000.11007.190310.0000AID1449628
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (67)

Processvia Protein(s)Taxonomy
fatty acid metabolic processBile salt export pumpHomo sapiens (human)
bile acid biosynthetic processBile salt export pumpHomo sapiens (human)
xenobiotic metabolic processBile salt export pumpHomo sapiens (human)
xenobiotic transmembrane transportBile salt export pumpHomo sapiens (human)
response to oxidative stressBile salt export pumpHomo sapiens (human)
bile acid metabolic processBile salt export pumpHomo sapiens (human)
response to organic cyclic compoundBile salt export pumpHomo sapiens (human)
bile acid and bile salt transportBile salt export pumpHomo sapiens (human)
canalicular bile acid transportBile salt export pumpHomo sapiens (human)
protein ubiquitinationBile salt export pumpHomo sapiens (human)
regulation of fatty acid beta-oxidationBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transportBile salt export pumpHomo sapiens (human)
bile acid signaling pathwayBile salt export pumpHomo sapiens (human)
cholesterol homeostasisBile salt export pumpHomo sapiens (human)
response to estrogenBile salt export pumpHomo sapiens (human)
response to ethanolBile salt export pumpHomo sapiens (human)
xenobiotic export from cellBile salt export pumpHomo sapiens (human)
lipid homeostasisBile salt export pumpHomo sapiens (human)
phospholipid homeostasisBile salt export pumpHomo sapiens (human)
positive regulation of bile acid secretionBile salt export pumpHomo sapiens (human)
regulation of bile acid metabolic processBile salt export pumpHomo sapiens (human)
transmembrane transportBile salt export pumpHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell activation involved in immune responseInterferon betaHomo sapiens (human)
cell surface receptor signaling pathwayInterferon betaHomo sapiens (human)
cell surface receptor signaling pathway via JAK-STATInterferon betaHomo sapiens (human)
response to virusInterferon betaHomo sapiens (human)
positive regulation of autophagyInterferon betaHomo sapiens (human)
cytokine-mediated signaling pathwayInterferon betaHomo sapiens (human)
natural killer cell activationInterferon betaHomo sapiens (human)
positive regulation of peptidyl-serine phosphorylation of STAT proteinInterferon betaHomo sapiens (human)
cellular response to interferon-betaInterferon betaHomo sapiens (human)
B cell proliferationInterferon betaHomo sapiens (human)
negative regulation of viral genome replicationInterferon betaHomo sapiens (human)
innate immune responseInterferon betaHomo sapiens (human)
positive regulation of innate immune responseInterferon betaHomo sapiens (human)
regulation of MHC class I biosynthetic processInterferon betaHomo sapiens (human)
negative regulation of T cell differentiationInterferon betaHomo sapiens (human)
positive regulation of transcription by RNA polymerase IIInterferon betaHomo sapiens (human)
defense response to virusInterferon betaHomo sapiens (human)
type I interferon-mediated signaling pathwayInterferon betaHomo sapiens (human)
neuron cellular homeostasisInterferon betaHomo sapiens (human)
cellular response to exogenous dsRNAInterferon betaHomo sapiens (human)
cellular response to virusInterferon betaHomo sapiens (human)
negative regulation of Lewy body formationInterferon betaHomo sapiens (human)
negative regulation of T-helper 2 cell cytokine productionInterferon betaHomo sapiens (human)
positive regulation of apoptotic signaling pathwayInterferon betaHomo sapiens (human)
response to exogenous dsRNAInterferon betaHomo sapiens (human)
B cell differentiationInterferon betaHomo sapiens (human)
natural killer cell activation involved in immune responseInterferon betaHomo sapiens (human)
adaptive immune responseInterferon betaHomo sapiens (human)
T cell activation involved in immune responseInterferon betaHomo sapiens (human)
humoral immune responseInterferon betaHomo sapiens (human)
positive regulation of T cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
adaptive immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independentHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of T cell anergyHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
defense responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
detection of bacteriumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-12 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of interleukin-6 productionHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protection from natural killer cell mediated cytotoxicityHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
innate immune responseHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
regulation of dendritic cell differentiationHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
antigen processing and presentation of endogenous peptide antigen via MHC class IbHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol phosphate metabolic processInositol hexakisphosphate kinase 1Homo sapiens (human)
phosphatidylinositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
negative regulation of cold-induced thermogenesisInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol phosphate biosynthetic processInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (24)

Processvia Protein(s)Taxonomy
protein bindingBile salt export pumpHomo sapiens (human)
ATP bindingBile salt export pumpHomo sapiens (human)
ABC-type xenobiotic transporter activityBile salt export pumpHomo sapiens (human)
bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
canalicular bile acid transmembrane transporter activityBile salt export pumpHomo sapiens (human)
carbohydrate transmembrane transporter activityBile salt export pumpHomo sapiens (human)
ABC-type bile acid transporter activityBile salt export pumpHomo sapiens (human)
ATP hydrolysis activityBile salt export pumpHomo sapiens (human)
cytokine activityInterferon betaHomo sapiens (human)
cytokine receptor bindingInterferon betaHomo sapiens (human)
type I interferon receptor bindingInterferon betaHomo sapiens (human)
protein bindingInterferon betaHomo sapiens (human)
chloramphenicol O-acetyltransferase activityInterferon betaHomo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
signaling receptor bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
peptide antigen bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
TAP bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
protein-folding chaperone bindingHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
inositol-1,3,4,5,6-pentakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol heptakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
protein bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
ATP bindingInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 1-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol hexakisphosphate 3-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol 5-diphosphate pentakisphosphate 5-kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
inositol diphosphate tetrakisphosphate kinase activityInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (28)

Processvia Protein(s)Taxonomy
basolateral plasma membraneBile salt export pumpHomo sapiens (human)
Golgi membraneBile salt export pumpHomo sapiens (human)
endosomeBile salt export pumpHomo sapiens (human)
plasma membraneBile salt export pumpHomo sapiens (human)
cell surfaceBile salt export pumpHomo sapiens (human)
apical plasma membraneBile salt export pumpHomo sapiens (human)
intercellular canaliculusBile salt export pumpHomo sapiens (human)
intracellular canaliculusBile salt export pumpHomo sapiens (human)
recycling endosomeBile salt export pumpHomo sapiens (human)
recycling endosome membraneBile salt export pumpHomo sapiens (human)
extracellular exosomeBile salt export pumpHomo sapiens (human)
membraneBile salt export pumpHomo sapiens (human)
extracellular spaceInterferon betaHomo sapiens (human)
extracellular regionInterferon betaHomo sapiens (human)
Golgi membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
endoplasmic reticulumHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
Golgi apparatusHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
cell surfaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
ER to Golgi transport vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
secretory granule membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
phagocytic vesicle membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
early endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
recycling endosome membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular exosomeHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
lumenal side of endoplasmic reticulum membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
MHC class I protein complexHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
extracellular spaceHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
external side of plasma membraneHLA class I histocompatibility antigen, B alpha chain Homo sapiens (human)
fibrillar centerInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
cytosolInositol hexakisphosphate kinase 1Homo sapiens (human)
nucleusInositol hexakisphosphate kinase 1Homo sapiens (human)
cytoplasmInositol hexakisphosphate kinase 1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (41)

Assay IDTitleYearJournalArticle
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1474166Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540209Volume of distribution at steady state in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540210Clearance in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1449628Inhibition of human BSEP expressed in baculovirus transfected fall armyworm Sf21 cell membranes vesicles assessed as reduction in ATP-dependent [3H]-taurocholate transport into vesicles incubated for 5 mins by Topcount based rapid filtration method2012Drug metabolism and disposition: the biological fate of chemicals, Dec, Volume: 40, Issue:12
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
AID1474167Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status2016Drug discovery today, Apr, Volume: 21, Issue:4
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
AID540211Fraction unbound in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1207622Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
AID540213Half life in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID540212Mean residence time in human after iv administration2008Drug metabolism and disposition: the biological fate of chemicals, Jul, Volume: 36, Issue:7
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
AID1207621Inhibition of L-type calcium channel measured using whole-cell patch clamp in guinea pig ventricular myocytes2012Journal of applied toxicology : JAT, Oct, Volume: 32, Issue:10
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (119)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's8 (6.72)18.2507
2000's39 (32.77)29.6817
2010's52 (43.70)24.3611
2020's20 (16.81)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 67.87

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index67.87 (24.57)
Research Supply Index4.99 (2.92)
Research Growth Index4.89 (4.65)
Search Engine Demand Index114.63 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (67.87)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials19 (14.96%)5.53%
Reviews25 (19.69%)6.00%
Case Studies8 (6.30%)4.05%
Observational4 (3.15%)0.25%
Other71 (55.91%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Clinical Trials (31)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
A Randomized, Double-blind, Active-compared Phase Ш Clinical Trial to Evaluate Clevidipine Butyrate Injectable Emulsion in the Treatment of Hypertensive Emergency and Sub-emergency [NCT05783557]Phase 3398 participants (Anticipated)Interventional2023-05-01Not yet recruiting
A Pilot Study to Evaluate the Effect of Changing Physiological Conditions on the Amplitude and/or Frequency of Myogenic Oscillations [NCT03719001]Early Phase 140 participants (Actual)Interventional2018-10-23Completed
Clevidipine for Vasoreactivity Evaluation of the Pulmonary Arterial Bed (CARVE) [NCT01121458]Phase 412 participants (Actual)Interventional2009-09-30Completed
Effect of Treatment of Pre-induction Hypertension on Hemodynamic Stability During Induction of General Anesthesia [NCT06063772]Phase 464 participants (Anticipated)Interventional2024-01-31Not yet recruiting
A Randomized, Single-blind, Positive Drug Parallel Controlled, Multi-center Clinical Study on the Efficacy and Safety of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergency and Sub-emergency [NCT05044364]Phase 310 participants (Anticipated)Interventional2021-10-11Not yet recruiting
The Evaluation of Patients With Acute Hypertension and Intracerebral Hemorrhage With Intravenous Clevidipine Treatment (ACCELERATE) [NCT00666328]Phase 337 participants (Actual)Interventional2008-06-30Completed
A Safety and Efficacy Study of Blood Pressure Control in Acute Heart Failure - A Pilot Study (PRONTO) [NCT00803634]Phase 3117 participants (Actual)Interventional2008-12-31Completed
Pre and or Post Operative Blood Pressure Control With Clevidipine (Cleviprexm Medicines Company) in Aortic Aneurysm / Dissection. [NCT01480531]0 participants (Actual)Interventional2011-12-31Withdrawn(stopped due to We elected to stop this study due to our inability to recruit suitable subjects.)
The Evaluation of Clevidipine in Patients Requiring ICP Monitoring and IV Antihypertensive Therapy [NCT01910532]Phase 40 participants (Actual)Interventional2010-04-30Withdrawn(stopped due to Sponsor discontinued the research)
A Safety and Efficacy Study of Blood Pressure Control in Acute Aortic Emergencies - A Pilot Study (PROMPT) [NCT01033370]Phase 45 participants (Actual)Interventional2009-11-30Terminated(stopped due to Project lacked funding.)
The Efficacy and Safety of Cleviprex in Ventriculostomy Patients Requiring IV Antihypertensive Therapy Investigator Initiated Trial [NCT01042574]Phase 40 participants (Actual)Interventional2010-05-31Withdrawn(stopped due to Unable to secure funding)
Comparative Effectiveness of Energy Doses in Critical Illness [NCT01369147]Phase 212 participants (Actual)Interventional2011-07-31Terminated(stopped due to This study was halted pending additional funding and ultimately was terminated due to difficulties with ongoing recruitment, etc.)
Efficacy Study of Clevidipine Assessing Its Postoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-2) [NCT00093262]Phase 3206 participants (Actual)Interventional2003-12-31Completed
Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Nitroglycerin as Active Comparator) (ECLIPSE-NTG) [NCT00093886]Phase 3629 participants (Actual)Interventional2004-04-30Completed
Evaluation of Clevidipine in the Postoperative Treatment of Hypertension Assessing Safety Events (With Nicardipine as Active Comparator) (ECLIPSE-NIC) [NCT00093925]Phase 3739 participants (Actual)Interventional2004-05-31Completed
A Randomized, Single Blind, Positive Parallel Controlled, Multicenter, Phase III Clinical Trial of Clevidipine Butyrate Injection in the Treatment of Hypertensive Emergencies [NCT04670809]Phase 3262 participants (Anticipated)Interventional2020-07-27Recruiting
Clevidipine in Aneurysmal Subarachnoid Hemorrhage, A Pilot Study [NCT00978822]Phase 25 participants (Actual)Interventional2009-06-30Terminated(stopped due to Difficult enrollment parameters, subsequently low enrollment. Decision to terminate trial.)
Efficacy Study of Clevidipine Assessing Its Preoperative Antihypertensive Effect in Cardiac Surgery (ESCAPE-1) [NCT00093249]Phase 3105 participants (Actual)Interventional2004-01-31Completed
Evaluation of Clevidipine in the Perioperative Treatment of Hypertension Assessing Safety Events (With Sodium Nitroprusside as Active Comparator) (ECLISPE-SNP) [NCT00093912]Phase 3739 participants (Actual)Interventional2004-06-30Completed
Clevidipine Infusion for Blood Pressure Management After Successful Revascularization in Acute Ischemic Stroke (CLEVER) [NCT05175547]Phase 380 participants (Anticipated)Interventional2021-11-01Recruiting
A Randomized Parallel Group Controlled Comparison Study of Clevidipine Versus Placebo or Standard of Care for Dyspnea and Blood Pressure Control in Acute Heart Failure (PRONTO II) [NCT04592380]Phase 30 participants (Actual)Interventional2014-08-31Withdrawn(stopped due to Product was divested to Chiesi USA, who decided to not move forward with study.)
Effect of Clevidipine on Intracranial Pressure, Cerebral Blood Flow, Brain Tissue Oxygenation and Brain Cellular Metabolism in Severely Hypertensive Patients With Acute Brain Injury [NCT01526876]Phase 40 participants (Actual)Interventional2011-11-30Withdrawn(stopped due to Terminated by Sponsor)
Clevidipine for Acute High Blood Pressure Control in Neurocritical Patients [NCT05168059]33 participants (Actual)Observational2017-01-01Completed
Clevidipine for Vasospasm After Subarachnoid Hemorrhage [NCT02011321]Phase 20 participants (Actual)Interventional2014-03-31Withdrawn
Evaluation of the Effect of Ultrashort-Acting Clevidipine in the Treatment of Patients With Severe Hypertension (VELOCITY) [NCT00369837]Phase 3131 participants (Actual)Interventional2006-09-30Completed
A Pilot Study to Evaluate Efficacy and Safety of Clevidipine in Neurosurgical Patients [NCT00952081]Phase 422 participants (Actual)Interventional2009-07-31Completed
Open Label Study to Assess the Efficacy, Safety and Dosing of Clevidipine in Pediatric Patients Undergoing Surgery [NCT01938547]Phase 4100 participants (Anticipated)Interventional2014-03-31Suspended
A Multicentre, Randomized, Double-blind, Parallel Design Phase III Study to Evaluate the Efficacy and Safety of Intravenous QLG2071 Versus Cleviprex® for Patients With Hypertensive Emergency and Sub-emergency [NCT05922436]Phase 3378 participants (Anticipated)Interventional2023-07-15Not yet recruiting
Clevidipine (Cleviprex®) Compared With Urapidil (Ebrantil®) for Blood Pressure Reduction in Patients With Primary Intracerebral Hemorrhage: A Randomized Controlled Trial [NCT03300479]Phase 40 participants (Actual)Interventional2017-06-15Withdrawn(stopped due to No patient enrolled. No study conduct due to lack of human resources.)
An Open-label Study in Patients Undergoing Cardiac Surgery to Evaluate the Effect of Bolus Clevidipine Administration (SPRINT) [NCT00799604]Phase 230 participants (Actual)Interventional2008-11-30Completed
An Open-label Trial of Clevidipine for Controlled Hypotension During Spinal Fusion [NCT01645111]Phase 2/Phase 350 participants (Actual)Interventional2012-06-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

TrialOutcome
NCT00666328 (10) [back to overview]Magnitude, Frequency and Duration of Systolic Blood Pressure Excursions (Calculated as Area Under the Curve [AUC]) Outside the Target Range Normalized Per Hour for the Duration of the Clevidipine Monotherapy Infusion
NCT00666328 (10) [back to overview]Mean Dose of Clevidipine During the Treatment Period
NCT00666328 (10) [back to overview]Median Dose of Clevidipine During the Treatment Period
NCT00666328 (10) [back to overview]Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine
NCT00666328 (10) [back to overview]Percentage of Participants Achieving a SBP of ≤160 mmHg Within 30 Minutes of Initiation of Clevidipine
NCT00666328 (10) [back to overview]Proportion of Patients Requiring an Additional or Alternative Antihypertensive Agent(s) With or Without Clevidipine
NCT00666328 (10) [back to overview]The Percentage of Patients Whose Systolic Blood Pressure is <90 mmHg Within 30 Minutes of the Initiation of Clevidipine Infusion
NCT00666328 (10) [back to overview]Percent Change From Baseline in Systolic Blood Pressure During the Initial 30 Minutes of Clevidipine Infusion
NCT00666328 (10) [back to overview]Percent Change in Heart Rate During 30 of Initiation of Clevidipine
NCT00666328 (10) [back to overview]Percent Time Blood Pressures Were Maintained Within the Target Range (Systolic Blood Pressure ≤160 mmHg to ≥140 mmHg) Over Each 24 Hour Period During Monotherapy Infusion of Clevidipine
NCT00799604 (7) [back to overview]Change in Heart Rate After Bolus 1 (Pre-anesthesia).
NCT00799604 (7) [back to overview]The Mean Maximum Absolute Change in Systolic Blood Pressure From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).
NCT00799604 (7) [back to overview]The Mean Maximum Percent Change in Systolic Blood Pressure From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).
NCT00799604 (7) [back to overview]The Percentage of Patients With Systolic Blood Pressure ≤85 mm Hg Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).
NCT00799604 (7) [back to overview]The Mean Percent Change in Systolic Blood Pressure From Baseline Over Time During the First 15 Minutes Following First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).
NCT00799604 (7) [back to overview]The Median Time to 5%, 10%, and 15% Systolic Blood Pressure Reduction From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 -Pre-anesthesia).
NCT00799604 (7) [back to overview]The Median Time to 50%, and, When Available, 90% Recovery From Maximum SBP Effect Following the First Bolus Dose of Clevidipine for Patients Who Achieved the Endpoints (Treatment Period 1, Bolus 1 - Pre-anesthesia).
NCT00803634 (11) [back to overview]SBP Area Under the Curve (AUC) Outside Prespecified Target Range
NCT00803634 (11) [back to overview]Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes
NCT00803634 (11) [back to overview]Time to Use Other IV Antihypertensives During the Study Drug Administration
NCT00803634 (11) [back to overview]Change From Baseline in Dyspnea (Measured By VAS) at Each Time Point
NCT00803634 (11) [back to overview]Number of Patients That Require Intubation During Study Drug Administration up to 96 Hours
NCT00803634 (11) [back to overview]Percentage Falling Below Lower Limit of SBP Target Range at Any Time During Study
NCT00803634 (11) [back to overview]Percentage Falling Below Lower Limit of SBP Target Range Within First 30 Minutes
NCT00803634 (11) [back to overview]Percentage of Patients Who Received Any Alternative IV Antihypertensive Drug at Any Time During Study Drug Treatment
NCT00803634 (11) [back to overview]Percentage of Patients With at Least One Episode of SBP < 90 mm Hg During Study Drug Administration (up to 96 Hours)
NCT00803634 (11) [back to overview]Percentage Reaching Prespecified Target Range Without Falling Below Lower Limit of Target Range Within First 30 Minutes
NCT00803634 (11) [back to overview]Percentage to First Achieve Initial Prespecified SBP Target Range [≥20 mm Hg and ≤40 mm Hg Apart] and 15% Reduction From Baseline Within First 30 Minutes
NCT00952081 (1) [back to overview]The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine is a Sole Antihypertensive Agent Used for Blood Pressure Control)
NCT00978822 (1) [back to overview]Ability to Control and Maintain Blood Pressure Within a Certain Range by the Drug Infusion.
NCT01369147 (7) [back to overview]Cumulative 28-day Energy Deficit
NCT01369147 (7) [back to overview]Mean Daily Energy Deficit
NCT01369147 (7) [back to overview]Number of Days in Hospital
NCT01369147 (7) [back to overview]Number of Days in Intensive Care Unit (ICU)
NCT01369147 (7) [back to overview]Number of Participants With Bloodstream Infection
NCT01369147 (7) [back to overview]Number of Participants With Hospital-acquired Infection
NCT01369147 (7) [back to overview]Ventilator Free Days
NCT01645111 (1) [back to overview]Time to Achieve Target MAP

Magnitude, Frequency and Duration of Systolic Blood Pressure Excursions (Calculated as Area Under the Curve [AUC]) Outside the Target Range Normalized Per Hour for the Duration of the Clevidipine Monotherapy Infusion

Total AUC-SBP captures the magnitude and duration of SBP either above the upper limit of the target SBP range at 160 mm Hg or below the lower limit of 140 mm Hg and normalized per hour for the duration of clevidipine infusion. A larger value for AUC-SBP indicates greater SBP variability outside the target range. (NCT00666328)
Timeframe: Duration of the study drug infusion (up to 96 hours)

Interventionmm Hg × min/hr (Mean)
Clevidipine347.7

[back to top]

Mean Dose of Clevidipine During the Treatment Period

Mean total dose of clevidipine from study drug initiation to the end of clevidipine treatment (NCT00666328)
Timeframe: Up to 96 hours

Interventionmilligrams (mg) (Mean)
Clevidipine260.28

[back to top]

Median Dose of Clevidipine During the Treatment Period

Mean total dose of clevidipine from study drug initiation to the end of clevidipine treatment (NCT00666328)
Timeframe: Up to 96 hours

Interventionmilligrams (mg) (Median)
Clevidipine116.32

[back to top]

Median Time to Achieve Target SBP Range (≤160 mmHg to ≥140 mmHg) Within 30 Minutes of Initiation of Clevidipine

The median time, in minutes, was estimated with its two-tailed 95% confidence interval from the time of the initiation of clevidipine infusion until the first observed SBP was achieved in the target range of ≤160 mmHg to ≥140 mmHg within the first 30 minutes of clevidipine treatment. If patients did not reach the blood pressure target range within the first 30 minutes, their data was considered censored at 30 minutes. If another IV and/or oral antihypertensive agent indicated for hypertension was administered less than 30 minutes prior to achieving the endpoint, the data was considered censored at the time when the additional or alternative antihypertensive agent was given. (NCT00666328)
Timeframe: Within 30 minutes of study drug initiation

Interventionminutes (Median)
Clevidipine5.5

[back to top]

Percentage of Participants Achieving a SBP of ≤160 mmHg Within 30 Minutes of Initiation of Clevidipine

The percentage of patients who reached SBP of ≤160 mmHg within the first 30 minutes of initiation of clevidipine infusion was summarized. If an additional or alternative IV antihypertensive agent and/or oral antihypertensive agent was administered for hypertension prior to a patient achieving SBP≤160 mmHg during the initial 30-minute treatment period, then the patient was considered to have failed to reach this efficacy endpoint. (NCT00666328)
Timeframe: Within 30 minutes of study drug initiation

Interventionpercent participants (Number)
Clevidipine97

[back to top]

Proportion of Patients Requiring an Additional or Alternative Antihypertensive Agent(s) With or Without Clevidipine

Additional or alternative antihypertensive agent(s) comprise the use of other antihypertensive agent(s) either with clevidipine (additional) or in place of clevidipine (alternative) for the indication of hypertension from the time of clevidipine initiation to clevidipine termination. For purposes of this analysis, additional or alternative antihypertensive agents did not include oral antihypertensives that were administered in order to transition IV clevidipine-treated patients to oral therapy during the transition period of the study. (NCT00666328)
Timeframe: Up to 96 hours

Interventionparticipants (Number)
Clevidipine18

[back to top]

The Percentage of Patients Whose Systolic Blood Pressure is <90 mmHg Within 30 Minutes of the Initiation of Clevidipine Infusion

(NCT00666328)
Timeframe: Within 30 minutes of the initiation of study drug infusion

Interventionpercent participants (Number)
Clevidipine0

[back to top]

Percent Change From Baseline in Systolic Blood Pressure During the Initial 30 Minutes of Clevidipine Infusion

Over the initial 30 minutes of the treatment period, the percent change from baseline (defined as immediately prior to study drug initiation) was summarized descriptively at 1, 2, 3, 4, 5, 6, 7, 10, 15, 20, 25, and 30 minutes after clevidipine initiation. Decreases in SBP from baseline were observed over the course of this time period. (NCT00666328)
Timeframe: Baseline through 30 minutes post initiation of clevidipine infusion

Interventionpercent change in SBP (Mean)
Baseline Through Initial 1 Min.Baseline Through Initial 2 Min.Baseline Through Initial 3 Min.Baseline Through Initial 4 Min.Baseline Through Initial 5 Min.Baseline Through Initial 6 Min.Baseline Through Initial 7 Min.Baseline Through Initial 10 Min.Baseline Through Initial 15 Min.Baseline Through Initial 20 Min.Baseline Through Initial 25 Min.Baseline Through Initial 30 Min.
Clevidipine-2.2-4.7-5.9-8.5-9.8-11.3-13.9-14.0-17.4-17.4-18.9-20.0

[back to top]

Percent Change in Heart Rate During 30 of Initiation of Clevidipine

Multiple timepoints were assessed (minutes 1, 2, 3, 4, 5, 10, 15, 20, 30) for analysis of percent change in heart rate during the initial 30 minutes. (NCT00666328)
Timeframe: From study drug initiation through each specified timepoint

Interventionpercent change (Mean)
Study Drug Initiation Through Initial 1 Min; n=35Study Drug Initiation Through Initial 2 Min; n=32Study Drug Initiation Through Initial 3 Min; n=35Study Drug Initiation Through Initial 4 Min; n=34Study Drug Initiation Through Initial 5 Min; n=34Study Drug Initiation Through Initial 6 Min; n=34Study Drug Initiation Through Initial 7 Min; n=34Study Drug Initiation Through Initial 10 Min; n=34Study Drug Initiation Through Initial 15 Min; n=35Study Drug Initiation Through Initial 20 Min, n=35Study Drug Initiation Through Initial 25 Min; n=35Baseline Through Initial 30 Mins; n=33
Clevidipine-0.4-0.7-0.30.22.12.62.55.65.56.25.44.9

[back to top]

Percent Time Blood Pressures Were Maintained Within the Target Range (Systolic Blood Pressure ≤160 mmHg to ≥140 mmHg) Over Each 24 Hour Period During Monotherapy Infusion of Clevidipine

The percent time that SBP was maintained within the SBP target range (≤160 mmHg to ≥140 mmHg) was summarized for each 24-hour period of monotherapy of clevidipine infusion through 96 hours (0 -≤24 h, 24-≤48 h, 48-≤72 h, 72-≤96 h). For purposes of this analysis, SBP data were available from all mITT patients for the overall infusion period and from 0 to ≤24 hours of infusion; however, data was only available for 8 patients from 24 to ≤48 hours, 4 patients from 48 to ≤72 hours and 1 patient from 72 to ≤96 hours due to the variability in infusion durations >24 hours across patients. (NCT00666328)
Timeframe: From study drug initiation through termination (up to 96 h)

Interventionpercent time (Mean)
0 -≤24 h of clevidipine infusion; n=3324-≤48 h of clevidipine infusion; n=848-≤72 h of clevidipine infusion; n=472-≤96 h of clevidipine infusion; n=1
Clevidipine51.9161.1246.9465.91

[back to top]

Change in Heart Rate After Bolus 1 (Pre-anesthesia).

The baseline heart rate was measured as the median of all the heart rate measurements within 60 seconds or at the start of the administration of Bolus 1. (NCT00799604)
Timeframe: Baseline up until the first 15 minutes following Bolus 1 (pre-anesthesia).

Interventionbeats per minute (bpm) (Mean)
Cohort 1: Clevidipine 250 μg (0.5 mL)11.0
Cohort 2: Clevidipine 500 μg (1.0 mL)3.1
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL)2.0

[back to top]

The Mean Maximum Absolute Change in Systolic Blood Pressure From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).

Blood Pressure was measured at 60, 45, 30, 0 seconds prior to first Bolus dose (Bolus 1), and every 5 seconds after Bolus 1 for 15 minutes. Baseline SBP of Bolus 1 is defined as, 'median of all measurements prior to or at the start of Bolus 1'. Locally weighted scatterplot smoothing (LOWESS) method was used to determine the minimum SBP value for each patient. Maximum absolute change is the minimum SBP value within 15 minutes from bolus 1 minus baseline value. (NCT00799604)
Timeframe: From start to 15 minutes of Bolus 1 dose of clevidipine (pre-anesthesia).

Interventionmm Hg (Mean)
Cohort 1: Clevidipine 250 μg (0.5 mL)-18.8
Cohort 2: Clevidipine 500 μg (1.0 mL)-37.0
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL of a 1:1 Sol)-15.8

[back to top]

The Mean Maximum Percent Change in Systolic Blood Pressure From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).

Blood Pressure was measured at 60, 45, 30, 0 seconds prior to first Bolus dose (Bolus 1), and every 5 seconds after Bolus 1 for 15 minutes. Baseline SBP of Bolus 1 is defined as, 'median of all measurements prior to or at the start of Bolus 1'. Locally weighted scatterplot smoothing (LOWESS) method was used to determine the minimum SBP value for each patient. Maximum percent change is defined as the maximum absolute change divided by the baseline value of bolus 1 and multiplied by 100. (NCT00799604)
Timeframe: From start to 15 minutes of Bolus 1 dose of clevidipine (pre-anesthesia).

Interventionpercent change (Mean)
Cohort 1: Clevidipine 250 μg (0.5 mL)-11.89
Cohort 2: Clevidipine 500 μg (1.0 mL)-22.10
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL of a 1:1 Sol)-8.91

[back to top]

The Percentage of Patients With Systolic Blood Pressure ≤85 mm Hg Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).

The percentage is calculated using the number of patients with a systolic blood pressure ≤85 mm Hg within 15 minutes from the initial Bolus 1 dose divided by the total number of patients who were treated with a Bolus 1 clevidipine, and multiplied by 100. (NCT00799604)
Timeframe: From start to 15 minutes of Bolus 1 dose of clevidipine (pre-anesthesia).

Interventionpercent patients (Number)
Cohort 1: Clevidipine 250 μg (0.5 mL)0
Cohort 2: Clevidipine 500 μg (1.0 mL)0
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL)0

[back to top]

The Mean Percent Change in Systolic Blood Pressure From Baseline Over Time During the First 15 Minutes Following First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 - Pre-anesthesia).

BP was measured at 60, 45, 30, 0 seconds prior to first Bolus dose (Bolus 1), and every 5 seconds after Bolus 1 for 15 minutes. Baseline SBP of Bolus 1 is defined as median of all measurements prior to or at the start of Bolus 1. SBP change (percent change) from baseline is calculated at each collection time point after bolus 1 dose for each patient. (NCT00799604)
Timeframe: From start to 15 minutes of Bolus 1 of clevidipine (pre-anesthesia).

,,
Interventionpercent change (Mean)
SBP 0.25 minutes after Bolus 1SBP 0.5 minutes after Bolus 1SBP 0.75 minutes after Bolus 1SBP 1 minute after Bolus 1SBP 1.5 minutes after Bolus 1SBP 2 minutes after Bolus 1SBP 3 minutes after Bolus 1SBP 5 minutes after Bolus 1SBP 7 minutes after Bolus 1SBP 15 minutes after Bolus 1
Cohort 1: Clevidipine 250 μg (0.5 mL)0.962.79-5.22-8.37-8.64-9.51-6.58-4.23-1.310.58
Cohort 2: Clevidipine 500 μg (1.0 mL)-0.10-2.41-9.09-12.29-19.40-20.36-17.95-11.08-6.77-0.33
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL)0.18-1.59-5.87-5.67-6.68-7.07-6.79-3.07-3.17-2.32

[back to top]

The Median Time to 5%, 10%, and 15% Systolic Blood Pressure Reduction From Baseline Within 15 Minutes From the First Bolus Dose of Clevidipine (Treatment Period 1, Bolus 1 -Pre-anesthesia).

BP was measured at 60, 45, 30, 0 seconds prior to first Bolus dose (bolus 1), and every 5 seconds after Bolus 1 for 15 minutes. Baseline SBP of bolus 1 is defined as median of all measurements prior to or at the start of Bolus 1. The time at which first target SBP reduction (ex. 5%) from baseline was reached was identified for each patient using fitted values from LOWESS method. Kaplan-Meier method was used to estimate the median time. Patients who never reached 5%, 10% or 15% reduction, withdrew from study or changed antihypertensive within 15 minutes were censored. (NCT00799604)
Timeframe: From start to 15 minutes of Bolus 1 of clevidipine (pre-anesthesia).

,,
Interventionminutes (Median)
5 % Reduction10% Reduction15% Reduction
Cohort 1: Clevidipine 250 μg (0.5 mL)0.91.3NA
Cohort 2: Clevidipine 500 μg (1.0 mL)0.81.11.2
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL)1.0NANA

[back to top]

The Median Time to 50%, and, When Available, 90% Recovery From Maximum SBP Effect Following the First Bolus Dose of Clevidipine for Patients Who Achieved the Endpoints (Treatment Period 1, Bolus 1 - Pre-anesthesia).

Analysis is of the time in minutes between the recorded time at the maximum absolute change and the time of the systolic blood pressure value at the first 50% recovery. The 50% recovery value is equal to the minimum recorded systolic blood pressure value plus 50% of the maximum amount of systolic blood pressure reduction (the Bolus 1 baseline value minus the value at the maximum absolute change). (NCT00799604)
Timeframe: Up to 15 minutes following the first bolus dose of clevidipine (pre-anesthesia).

,,
Interventionminutes (Median)
Time to 50% recovery in SBPTime to 90% recovery in SBP
Cohort 1: Clevidipine 250 μg (0.5 mL)1.85.2
Cohort 2: Clevidipine 500 μg (1.0 mL)2.96.8
Cohort 3: Clevidipine 125 μg (0.25 mL or 0.5 mL Sol)2.5NA

[back to top]

SBP Area Under the Curve (AUC) Outside Prespecified Target Range

The magnitude and duration of SBP excursions was calculated as the area under the curve (AUC) for each patient, using the trapezoidal rule, related to time (in minutes) that each patient's SBP was outside the target range. AUC was determined based on data collected from the initiation of study medication through the end of monotherapy treatment up to 96 hours, normalized per hour, and expressed as mmHg × minute/hour. (NCT00803634)
Timeframe: Initiation of study drug through end of monotherapy (up to 96 hours)

Interventionmm Hg x min/h (Mean)
Clevidipine494.96
Standard of Care966.15

[back to top]

Time to First Achieve Initial Prespecified SBP Target Range and 15% Reduction From Baseline Within First 30 Minutes

Time to first achieve the initial pre-specified systolic blood pressure (SBP) target range and a 15% SBP reduction from baseline is the time in minutes between the initiation of study medication and the time the patient first achieved both components. Median time was estimated using Kaplan Meier method. 95% two-sided confidence interval of the median time is from 'Simon and Lee, 1982'. If patients did not reach both components within 30 minutes from the initial treatment with study medication, or another antihypertensive agent was administered, the patient was censored at 30 minutes or the time when another antihypertensive agent is given, whichever came first. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionMinutes (Median)
Clevidipine15.0
Standard of CareNA

[back to top]

Time to Use Other IV Antihypertensives During the Study Drug Administration

The length of time to use other IV antihypertensive agents was defined as the duration in hours from the initiation of study drug through the time when any other concomitant IV antihypertensive agent was administered, thus, representing the time period without use of any other concomitant IV antihypertensive agent. Median time to use other IV antihypertensive agents was obtained using Kaplan-Meier method. If a patient did not receive any concomitant IV antihypertensive during the 96-hour treatment period, this patient was considered censored at 96 hours. If study drug was stopped less than 96 hours and the patient has no concomitant IV antihypertensive agent, the patient was considered censored when study drug was stopped. (NCT00803634)
Timeframe: Initiation of study drug through any other concomitant IV antihypertensive agent administered, up to 96 hours

InterventionHours (Median)
ClevidipineNA
Standard of Care5.7

[back to top]

Change From Baseline in Dyspnea (Measured By VAS) at Each Time Point

A validated visual analog scale (VAS) with a horizontal ruler showing increments from 0 to 100 mm with 0 = Best and 100 = Worst was used. The test was asked from the patient's perspective and had to be administered with patient sitting. Relative change in VAS from baseline is the value at each time point minus the baseline value. Relative change from baseline was summarized descriptively (with associated two-tailed 95% CIs of the mean values) at 15, 30 and 45 minutes and at 1, 2, 3 hours and 12 hours, and 1 hour post termination of study drug treatment. (NCT00803634)
Timeframe: Baseline (immediately prior to study drug administration) through 1 hour after study drug termination

,
Interventionmillimeters (mm) (Mean)
Baseline Through Initial 15 Min- CLV n=44;SOC n=38Baseline Through Initial 30 Min- CLV n=43;SOC n=39Baseline Through Initial 45 Min- CLV n=43;SOC n=39Baseline Through Initial 1 H- CLV n=41;SOC n=38Baseline Through Initial 2 H- CLV n=29;SOC n=29Baseline Through Initial 3 H- CLV n=14;SOC n=22Baseline Through Initial 12 H- CLV n=0;SOC n=7Baseline Through 1 H Post Drug- CLV n=41;SOC n=33
Clevidipine-18.6-28.8-37.1-43.6-45.2-47.9NA-50.1
Standard of Care-16.1-22.8-27.9-34.6-35.3-40.5-57.9-50.1

[back to top]

Number of Patients That Require Intubation During Study Drug Administration up to 96 Hours

The number of patients requiring intubation was calculated based on the total number of mITT patients. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPatients (Number)
Clevidipine0
Standard of Care0

[back to top]

Percentage Falling Below Lower Limit of SBP Target Range at Any Time During Study

The percentage of patients in whom the SBP fell below the lower limit of the prespecified target range at any time during the entire study drug treatment period (up to 96 hours) was calculated within each treatment group using the number of mITT patients achieving the endpoint divided by the number of mITT patients and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine68.2
Standard of Care70.7

[back to top]

Percentage Falling Below Lower Limit of SBP Target Range Within First 30 Minutes

The percentage of patients in whom the SBP fell below the lower limit of the prespecified target range at any time during the first 30 minutes was calculated within each treatment group using the number of mITT patients achieving the endpoint divided by the number of mITT patients and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine34.1
Standard of Care2.4

[back to top]

Percentage of Patients Who Received Any Alternative IV Antihypertensive Drug at Any Time During Study Drug Treatment

The percentage of patients who received any alternative IV antihypertensive drug at any time during the study drug treatment period (up to 96 hours) was calculated using mITT patients within each treatment group. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine15.9
Standard of Care51.2

[back to top]

Percentage of Patients With at Least One Episode of SBP < 90 mm Hg During Study Drug Administration (up to 96 Hours)

The percent of patients with at least one episode of SBP <90 mm Hg was calculated as the number of mITT patients who had at least one episode of SBP<90 mm Hg during study drug administration up to 96 hours divided by mITT patients, and multiplied by 100 for each treatment group. (NCT00803634)
Timeframe: Initiation through termination of study drug (up to 96 hours)

InterventionPercentage of patients (Number)
Clevidipine5.9
Standard of Care1.9

[back to top]

Percentage Reaching Prespecified Target Range Without Falling Below Lower Limit of Target Range Within First 30 Minutes

The percentage of patients reaching this endpoint was calculated within each treatment group using the number of mITT patients reaching the endpoint divided by the number of mITT patients, and multiplied by 100. Two-tailed 95% CIs were computed for these percentages. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine45.5
SOC IV Therapy51.2

[back to top]

Percentage to First Achieve Initial Prespecified SBP Target Range [≥20 mm Hg and ≤40 mm Hg Apart] and 15% Reduction From Baseline Within First 30 Minutes

Analysis of the percentage of patients achieving both components of this composite endpoint (attainment of the initial prespecified SBP target range and a 15% reduction in SBP from baseline) was calculated within each treatment group using the number of mITT patients achieving the SBP reduction goal divided by the number of mITT patients, and multiplied by 100. (NCT00803634)
Timeframe: Initiation of study drug through the initial 30-minutes

InterventionPercentage of patients (Number)
Clevidipine70.5
Standard of Care36.6

[back to top]

The Primary Endpoint of This Trial is the Proportion of Patients Who Did Not Require Rescue Antihypertensive Medication to Maintain SBP Below 130 mmHg (i.e. Clevidipine is a Sole Antihypertensive Agent Used for Blood Pressure Control)

(NCT00952081)
Timeframe: intraoperatively and 90 min after surgery

Interventionparticipants (Number)
Clevidipine,Brain Tumor,Hypertension21

[back to top]

Ability to Control and Maintain Blood Pressure Within a Certain Range by the Drug Infusion.

"All patients reached the SBP target after initiation of the first infusion within 14.2 ± 6.4 min (n = 5, range 7-22 min)~Study closed October 2012" (NCT00978822)
Timeframe: 30 minutes

Interventionmin (Mean)
Clevidipine14.2

[back to top]

Cumulative 28-day Energy Deficit

The daily energy deficit of kilocalories was calculated by subtracting the calculated mean daily Measured Resting Energy Expenditure (measured using a metabolic cart) from the actual daily energy intake obtained from participant nutrition intake records. The cumulative energy deficit is the sum of daily energy deficits during the time participants were hospitalized, up to 28 days. (NCT01369147)
Timeframe: Up to Day 28

Interventionkilocalories (kcal) (Mean)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE2631
Parenteral Nutrition Energy Dose at 1.0 x Measured REE11511.50
Parenteral Nutrition Energy Dose at 1.3 x Measured REE2414.75

[back to top]

Mean Daily Energy Deficit

The daily energy deficit of kilocalories was calculated by subtracting the calculated mean daily Measured Resting Energy Expenditure (measured using a metabolic cart) from the actual daily energy intake obtained from participant nutrition intake records. The mean daily energy deficit was calculated during the time participants were hospitalized, up to 28 days. (NCT01369147)
Timeframe: Up to Day 28

Interventionkcal/day (Mean)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE647.33
Parenteral Nutrition Energy Dose at 1.0 x Measured REE1065.75
Parenteral Nutrition Energy Dose at 1.3 x Measured REE1076.50

[back to top]

Number of Days in Hospital

The hospitalization length of stay (in days) is presented here for each study arm. (NCT01369147)
Timeframe: Up to Day 28

Interventiondays (Mean)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE27.33
Parenteral Nutrition Energy Dose at 1.0 x Measured REE25.00
Parenteral Nutrition Energy Dose at 1.3 x Measured REE17.75

[back to top]

Number of Days in Intensive Care Unit (ICU)

The ICU length of stay (in days) is presented here for each study arm. (NCT01369147)
Timeframe: Up to 28 Days

Interventiondays (Mean)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE7.33
Parenteral Nutrition Energy Dose at 1.0 x Measured REE14.25
Parenteral Nutrition Energy Dose at 1.3 x Measured REE4.00

[back to top]

Number of Participants With Bloodstream Infection

The count of participants acquiring a bloodstream infection during the study period is presented here. (NCT01369147)
Timeframe: Up to Day 28

InterventionParticipants (Count of Participants)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE1
Parenteral Nutrition Energy Dose at 1.0 x Measured REE0
Parenteral Nutrition Energy Dose at 1.3 x Measured REE0

[back to top]

Number of Participants With Hospital-acquired Infection

The number of participants with a hospital-acquired infection during the study period is presented here. (NCT01369147)
Timeframe: Up to Day 28

InterventionParticipants (Count of Participants)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE1
Parenteral Nutrition Energy Dose at 1.0 x Measured REE0
Parenteral Nutrition Energy Dose at 1.3 x Measured REE1

[back to top]

Ventilator Free Days

The mean number of ICU ventilator-free days among participants. (NCT01369147)
Timeframe: Up to Day 28

Interventiondays (Mean)
Parenteral Nutrition Energy Dose at 0.6 x Measured REE20.67
Parenteral Nutrition Energy Dose at 1.0 x Measured REE19.75
Parenteral Nutrition Energy Dose at 1.3 x Measured REE17.25

[back to top]

Time to Achieve Target MAP

The time between start of clevidipine infusion and patient reaching target mean arterial pressure (MAP) at 55-65 mmHg (NCT01645111)
Timeframe: First 30 minutes of infusion

Interventionminutes (Mean)
Clevidipine9.2

[back to top]